This open-label, blinded study was performed to evaluate the efficacy and tolerability of barnidipine at a titrated dose of 10 − 15 mg once daily for 8 weeks in the treatment of essential hypertension in 40 Thai patients. ‘Office’ blood pressure (BP) and 24-h ambulatory BP measurements were recorded. A systolic BP/ diastolic BP (SBP/DBP) reduction of 18.0 ± 13.6/9.1 ± 6.6 mmHg was obtained. The full response rate among patients with systolic and diastolic hypertension was 63% using either SBP or DBP criteria, and 54% using both SBP and DBP criteria. One of the two patients with isolated systolic hypertension had a full response, and the BP in two of the three patients with isolated diastolic hypertension was normalized. The trough-to-peak ratio and smoothness index for SBP/DBP were acceptable (0.76 ± 0.63/0.55 ± 0.26 and 1.2 ± 0.4/1.2 ± 0.3, respectively). In conclusion, once-daily barnidipine monotherapy provides effective 24-h BP control and is generally well tolerated in ambulatory patients.
HanssonLLindholmLHEkbomTDahlofBLankeJScherstenB: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999; 354: 1751–1756
2.
BrownMJPalmerCRCastaigneAde LeeuwPWManciaGRosenthalT: Morbidity and mortality in patients randomised to doubleblind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000; 356: 366–372
3.
WangJGStaessenJAGongLLiuL: Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med2000; 160: 211–220
4.
BirkenhargerWHStaessenJAGasowskiJde LeeuwPW: Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol2000; 13: 232–237
5.
HanssonLZanchettiACarruthersSGDahlofBElmfeldtDJuliusS: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998; 351: 1755–1762
6.
TuomilehtoJRastenyteDBirkenhagerWHThijsLAntikainenRBulpittCJ: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med1999; 340: 677–684
7.
StaessenJAThijsLFagardRHBirkenhagerWHArabidzeGBabeanuS: Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension1998; 32: 404–409
8.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002; 288: 2981–2997
9.
ManciaGZanchettiAAgabiti-RoseiEBenemioGde CesarisRFogariR: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation1997; 95: 1464–1470
10.
BianchiSBigazziRBaldariGSgherriGCampeseVM: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens1994; 7: 23–29
11.
O'BrienEAtkinsNStaessenJ: State of the market. A review of ambulatory blood pressure monitoring devices. Hypertension1995; 26: 835–842
12.
PickeringTG: Blood pressure measurement and detection of hypertension. Lancet1994; 344: 31–35
13.
AsmarRZanchettiA: Guidelines for the use of self-blood pressure monitoring: a summary report of the First International Consensus Conference. Groupe Evaluation & Measure of the French Society of Hypertension. J Hypertens2000; 18: 493–508
ParatiGOmboniSRizzoniDAgabiti-RoseiEManciaG: The smoothness index: a new, reproducible and clinically relevant measure of homogeneity of blood pressure reduction with treatment for hypertension. J Hypertens1998; 16: 1685–1691
16.
RoseMMcMahonFG: Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens1990; 3: 151–155
17.
MeredithPAElliottHL: FDA guidelines on trough: Peak ratios in the evaluation of anti-hypertensive agents. United States Food and Drug Administration. J Cardiovasc Pharmacol1994; 23 (Suppl 5): S26–S30
18.
MyersMG: Suggested guidelines for determining the trough-to-peak ratio of antihypertensive drugs. Am J Hypertens1996; 9: 76S–82S
19.
MorganT (ed): 24-Hour Blood Pressure Control: Its Importance, Its Determination, and The Use of the Trough-To-Peak Ratio.Oxford: Adis International1998; pp 15–28
20.
NeutelJMSmithDHGWeberMA: What are the approaches for evaluating antihypertensive treatment by 24 h ambulatory blood pressure monitoring?Blood Press Monit1999; 4 (Suppl 2): S23–S28
21.
LiauCSChienKLChaoCLLeeTM: Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients. J Int Med Res2002; 30: 330–336
22.
KuwajimaIAbe K for the J-MUBA Study Group: Effects of the long-acting calcium channel blocker barnidipine hydrochloride on 24-h ambulatory blood pressure. Blood Press Monit2002; 7: 63–65
23.
HartWHolwerdaNJ: Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: a multicenter, double-blind, placebo-controlled, dose-ranging study. Dutch Barnidipine Multicenter Study Group. Cardiovasc Drugs Ther1997; 11: 637–643
24.
NaberFBHageRMortelmansJ: Barnidipine monotherapy and combination therapy in older patients with essential hypertension: a long-term study. Int J Clin Prac2000; 114 (Suppl): 27–35
25.
SpiekerC: Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension. Blood Press1998; 7 (Suppl 1): 15–21
26.
Van ZwietenPA: Pharmacological profile of barnidipine: a single optical isomer dihydropyridine calcium antagonist. Blood Press1998; 7 (Suppl 1): 5–8
27.
ManciaGOmboniSRavogliAParatiGZanchettiA: Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press1995; 4: 148–156
28.
CoatsAJRadaelliAClarkSJConwayJSleightP: The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens1992; 10: 385–391
29.
ReidJLBainbridgeADMacFadyenRJ: The contribution of ambulatory blood pressure measurement to the evaluation of new antihypertensive drugs. J Hypertens1991; 9 (Suppl 8): S54–S56
WatanabeNImaiYNagaiKTsujiISatohHSakumaM: Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke1996; 27: 1319–1327
32.
ImaiYAbeKNishiyamaASekinoMYoshinagaK: Evaluation of the anti-hypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24 h, daytime, and nighttime. Am J Hypertens1997; 10: 1415–1419
33.
WhiteWB: Analysis of ambulatory blood pressure data in antihypertensive drug trials. J Hypertens1991; 9 (Suppl 1): S27–S32
